SYNAIRGEN

• 72110 - Research and experimental development on biotechnology

Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19... We are a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta (IFN-β) for the treatment of severe viral lung infections as potentially the first host-directed, broad-spectrum antiviral treatment delivered directly into the lungs... Synairgen has developed and is testing an inhaled formulation of IFN-β designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.

Also known as: SYNAIRGEN PLC, Synairgen Research ltd, synairgen.com

Previous names: SYNAIRGEN RESEARCH PLC

Registration numbers: 05233429 (CH), 4793696 (W), 5233429 (W)

VAT numbers: 849 7368 64

Primary location: Southampton United Kingdom